HCMSG - Hepatitis C Mentor & Support Group, Inc.

  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us
  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us

Liver Cancer Risk Lingers Even After HCV Eradication

11/23/2021

0 Comments

 
Neil Osterweil
November 17, 2021  MEDSCAPE

Although the risk for liver cancer diminishes for patients with hepatitis C virus (HCV) infections for whom virus is eliminated with direct-acting antiviral (DAA) drugs, these patients are not out of the woods, and those who do not have a sustained viral response (SVR) are at substantially higher risk of developing hepatocellular carcinoma (HCC), results of a large study show.
Among the patients with liver cirrhosis from HCV infections treated at 30 centers in Italy, a large percentage had an SVR after treatment with DAA drugs. Only a small percentage of this group subsequently developed HCC.
In contrast, not having an SVR was associated with a more than sevenfold higher risk for liver cancer, said Loreta A. Kondili, MD, PhD, from the Center for Global Health at the Istituto Superiore di Sanità, in Rome, Italy, during a presentation of the findings at The Liver Meeting 2021: American Association for the Study of Liver Diseases (AASLD), held online.
"Failure to achieve SVR after DAA treatment is strongly associated with the probability of HCC development. Older age, [HCV] genotype 3, and low platelet counts and albumin levels are independent factors of HCC development despite viral eradication," she said.

TO CONTINUE: 
https://www.medscape.com/viewarticle/963101fbclid=IwAR2QowyYfUqAeoNpDsxVI9zPR3xgLvpbNDKcd81IngJOqP7vPLGN-xHZyh8

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021

    Categories

    All

    RSS Feed

Privacy Policy
Disclaimer:  Information given by Hepatitis C Mentor and Support Group is not a substitute for advice given by your physician or health care provider.  We do not endorse any doctor, hospital, medical group, or treatment.